Skip to main content

Table 1 Baseline patients’ characteristics

From: Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy

Variable

A/V [n = 52 (%)]

CI

A/N [n = 50 (%)]

CI

P value

Demographic

 Age (mean ± SD) years

57.5 ± 10.7

[54.5, 60.5]

59.4 ± 10.4

[56.4, 62.3]

0.382

 Sex

  Male

18 (34.6)

 

19 (38.0)

 

0.722

  Female

34 (65.4)

 

31 (62.0)

  

BMI (mean ± SD)

31.9 ± 5.0

[30.5, 33.3]

31.7 ± 6.1

[30.0, 33.5]

0.859

CV history

 HTN

  Chronic

49 (94.2)

 

48 (96.0)

 

0.679

  Naive

3 (5.8)

 

2 (4.0)

  

 DM

21 (40.4)

 

14 (28.0)

 

0.188

 Dyslipidemia

29 (55.8)

 

34 (68.0)

 

0.204

 Dyslip.TT

  Rosuvastatin

22 (42.3)

 

31 (62.0)

 

0.155

  Atorvastatin

8 (15.4)

 

5 (10.0)

  

  Atorvastatin/EZT

2 (3.8)

 

0 (0.0)

  

  No

20 (38.5)

 

14 (28.0)

  

 AF

7 (13.5)

 

6 (12.0)

 

0.825

 Smoking

  Smoker

5 (9.6)

 

5 (10.0)

 

0.996

  Non-smoker

44 (84.6)

 

42 (84.0)

  

  Ex-smoker^

3 (5.8)

 

3 (6.0)

  
  1. A/V, Amlodipine/Valsartan; A/N, Amlodipine/Nebivolol; BMI, body mass index, CV, cardiovascular; HTN, hypertension; TT, treatment; DM, diabetes mellitus; IHD, ischemic heart disease; AF, atrial fibrillation; Dyslip, dyslipidemia; EZT, ezetimibe
  2. ^Ex-smoker; smoking cessation ≥ 6 month
  3. *A p-value less than or equal 0.05 is statistically significant